Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Not yet recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Carcinoma, Hepatocellular 41Carcinoma, Non-Small-Cell Lung 31Triple Negative Breast Neoplasms 23Nasopharyngeal Carcinoma 23Stomach Neoplasms 22Esophageal Neoplasms 20Esophageal Squamous Cell Carcinoma 19Breast Neoplasms 18Squamous Cell Carcinoma of Head and Neck 14Uterine Cervical Neoplasms 12Colorectal Neoplasms 12Sarcoma 10Pancreatic Neoplasms 9Lung Neoplasms 9Recurrence 7Neoplasm Metastasis 7Melanoma 6Liver Neoplasms 6Hodgkin Disease 6Cholangiocarcinoma 6Biliary Tract Neoplasms 5Advanced Gastric Cancer 5Small Cell Lung Carcinoma 4Osteosarcoma 4Neoplasms 4Locally Advanced Gastric Cancer 4Advanced Solid Tumor 4Solid Tumor 3Respiratory Tract Diseases 3Rectal Neoplasms 3

Interventions

irinotecan sucrosofate 1camrelizumab 1Radiotherapy 1Capecitabine 1Bevacizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Rectal Cancer Patients × camrelizumab × Clear all
NCT07521605 2026-04-13

Short-Course Radiotherapy, Nal-IRI, Capecitabine, and Camrelizumab for Locally Advanced MSS Rectal Cancer

Guangdong Provincial People's Hospital

Phase 2 Not yet recruiting
44 enrolled
Gastrointestinal

Rectal Cancer Patients

Data powered by HemOnc (CC BY 4.0) Colophon âš¡